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Abstract 
 
Objectives: To identify United Kingdom (UK)-specific research priorities in the field of 
Bone Conduction Hearing Devices (BCHDs).  
Method: Narrative summary of the discussions and outcomes of a UK BCHD research 
workshop. The workshop was organised on 8th September 2016 under the auspices of the 
National Institute for Health Research (NIHR) Clinical Research Network (CRN) ENT 
Specialty group and Royal College of Surgeons (RCS) Clinical Research Initiative. 
Representatives from a wide range of patient and professional groups from the UK and 
abroad were invited to attend. Main outcome measures were: Research priorities and 
approaches in the field of BCHDs. 
Results: Key research questions in the field of BCHDs are: 1) What are the existing national 
BCHD practices? 2) What are the patient information and support needs on BCHDs? 3) 
Which outcomes should be measured across clinical studies in the field of BCHDs? The 
workshop suggested the following approaches to address these priorities: 1) A service 
evaluation of current UK BCHD practice; development of a national registry of BCHDs; 2) 
Qualitative research to understand patient information and support needs; development of 
patient decision support tools 3) Development of core outcome sets (COSs) for BCHDs. 
Discussion: Building upon the framework of the recent UK Research Agenda for ENT, 
Hearing and Balance, patients and professionals defined key UK-specific research priorities 
and approaches in the field of BCHDs. This approach promotes engagement, buy-in, national 
collaboration and thereby value of future BCHD research. 
 
Keywords: Research priorities; Research agenda; Bone Conduction Hearing Devices; 
Hearing; Hearing implants; Consensus.  
  
Introduction  
The recent 2016 Bone Conduction Hearing Device (BCHD) commissioning policy (NHS 
England, 2016) sets the criteria for BCHD service delivery in England and as such 
determines the care received by patients with hearing loss within the NHS. In creating this 
policy, NHS England reviewed the evidence for BCHDs including whether they represent an 
efficient use of NHS resources. Whilst criteria were set, the commissioning policy (NHS 
England, 2016) highlights the lack of high-quality research on clinical and cost-effectiveness 
of BCHDs. Such research is key to developing the evidence base on BCHDs so that future 
commissioning policies can make informed decisions, based on strong evidence and help 
deliver the best care for patients within the available resources. With high quality research 
calling upon (competitive) funding as well as (limited) capacity, it is important to prioritise 
future research around BCHDs.   
 
The 2015 UK Research Agenda for ENT, Hearing and Balance care identified hearing loss as 
one of the next decade’s key research priorities (GENERATE, 2015; Bohm et al., 2016). 
Recognising that this broad topic needed further refinement, taking into context current 
policy and research activity, the National Institute for Health Research (NIHR) Clinical 
Research Network (CRN) ENT Specialty group organised a workshop with representatives 
from a wide range of patient and professional groups active in the field of BCHDs. This 
workshop aimed to identify UK-specific research priorities in the field of Bone Conduction 
Hearing Devices (BCHDs). This paper reports on the discussions of this workshop and the 
research priorities and approaches identified.  
 
Method 
Study design 
  
Narrative summary of the BCHD research workshop discussion. 
Setting 
The workshop was held on the 8th September 2016, under the auspices of NIHR CRN ENT 
Specialty Group (NIHR, 2016a) and the Royal College of Surgeons (RCS) Clinical Research 
Initiative (RCS, 2016).  
Participants 
Using purposive sampling a broad representation of UK professionals active in the field of 
BCHDs, international experts and patient representatives from a BCHD interest group were 
invited to attend the workshop. Participants were invited via email invitation and telephone. 
For the discussions participants were allocated to four groups, aiming at equal representation 
from the range of stakeholders. 
Workshop 
The workshop started with four presentations: 1) Objectives of the workshop; 2) Summary of 
the 2016 BCHD commissioning policy and a review and quality assessment of the existing 
evidence on BCHDs; 3) An international perspective on BCHD research; and 4) How to 
facilitate the group discussions.  
Each group was then encouraged to consider and discuss two main areas:  
1) What are the key questions in the field of BCHDs that need to be addressed by research? 
2) How should these questions be addressed? 
Finally, a representative from each group presented a summary of their groups’ discussion to 
all participants, who were encouraged to ask questions and stimulate further discussion. 
Notes were taken on a flip chart stand, in real time, visible to all attendees. The workshop 
lasted 2 hours 30 minutes (Figure 1).  
 
  
 
Figure 1: Bone Conduction Hearing Device (BCHD) research workshop held at the Royal 
College of Surgeons (RCS) 
 
Analysis and write-up  
Notes taken during the meeting were summarised by 2 authors (RM and PD) and synthesised 
into a structured narrative. This narrative was reviewed and commented upon by all other 
authors, with any discrepancies being resolved by discussion and consensus.  
Ethics 
For the involvement of patients and professionals in planning or advising on research, ethical 
approval and formal consent is not required and was therefore not sought (NIHR, 2016b; 
NIHR, 2015).  
 
Results 
Eighteen UK and two international professionals and two patient representatives, took part in 
the workshop. They represented all relevant UK stakeholder groups in BCHD (Table 1).  
 
 
  
Name Role Region  
Danny Hind  Assistant director, Clinical Trials Research Unit  Sheffield  
Munyia Dimairo  Medical Statistician, Clinical Trials Research Unit  Sheffield  
Sue Jowett Senior Lecturer Health Economics  Birmingham  
Kevin Peters  Commissioner  Yorkshire and Humber  
Sue Archibold  Chief Executive, The Ear Foundation  National  
Melanie Gregory  Appointed Chief Executive, The Ear Foundation  National  
Rupan Banga ENT Consultant  Birmingham  
Panagiotis Dimitriadis ENT Academic Clinical Fellow  Sheffield  
Rishi Mandavia  ENT Academic Clinical Fellow, NICE Scholar, Policy expert  London  
Caroline Mitchell  General Practitioner  Sheffield  
Anand Kasbekar ENT Senior Fellow Cambridge 
Padraig Kitterick  Senior Research Fellow  Nottingham  
Myrthe Hol International expert on BCHDs, Chair of the Dutch BCHD 
guideline and  
Nijmegen, Netherlands  
Gerard O'Donoghue Professor of ENT   Nottingham  
Ivo Kruyt PhD Student, ENT Trainee  Nijmegen, Netherlands  
Peter Monksfield  ENT Consultant  Birmingham  
Jaydip Ray  Professor of ENT   Sheffield  
Anne Schilder  Professor of ENT  London  
Penny Hill-Feltham Audiologist   Manchester   
Amanda Hall  Audiologist   Birmingham 
Rowena Egan Patient representative  London  
Anne Sargent Patient representative London  
Table 1: Stakeholder list, including role(s) and location 
 
Key research questions in the field of BCHDs  
a) What are the existing national BCHD practices? 
Participants noted that although an estimated 7,000 UK patients have been implanted with 
BCHDs (The Ear Foundation, 2015) data are lacking on: the current patient pathway, 
numbers and types of BCHDs implanted across UK regions, patient demographics, outcomes 
including long term safety and costs. It was felt that collecting such information is essential 
for: evaluating clinical and cost-effectiveness of BCHDs, comparing outcomes of different 
devices, early detection of risks and faulty implants, establishing appropriate patient selection 
and priority patient populations. Giving patients access to this information would help 
  
empower them and involve them in making decisions about their treatment. From a policy 
and commissioning perspective, identifying national practices would also help recognise 
variations in service provision and variations in patient pathways, including patient follow-
up. Information on costs and patient outcomes would be critical for cost-effectiveness 
analyses, which are valued by policy makers and guideline developers, including the National 
Institute for Health and Care Excellence (NICE).  
 
b) What are the patient information and support needs on BCHDs? 
Participants highlighted that non-specialist professionals often lack knowledge about hearing 
loss and BCHDs so it can be difficult for potential patients to access information about 
treatment options. There was felt to be a need for improved patient information pre-
implantation on the risks and benefits of BCHDs, and post-implantation on the practical 
aspects of BCHDs and managing hearing loss, to obtain maximum benefit from devices. 
Information provision and access to support was felt to be patchy across the country and 
different models of patient support, such as peer support groups, websites and expert patients, 
were discussed. It was felt that further research is required to determine the optimal model for 
providing information and supporting patients. 
 
c) Which outcomes should be measured across clinical studies in the field of BCHDs? 
Currently, there is no consistency across UK and international centres or in the scientific 
literature, in the outcomes assessed following BCHD implantation nor in the instruments 
used to measure these outcomes. This lack of standardisation in reporting outcomes in 
BCHDs impacts on clinicians’ ability to make shared decisions with their patients, as it 
makes it very difficult to inform patients about the likely outcomes of treatment based upon 
previous experiences. This research need was also highlighted in the 2015 UK Research 
  
Agenda for ENT, Hearing and Balance care (GENERATE, 2015). Regarding the instruments 
to measure these outcomes, it was felt that there is a paucity of validated instruments 
appropriate for measuring Quality of Life (QoL) in patients implanted with a BCHD. Generic 
QoL instruments such as the SF-36 or EQ-5D, were considered not sensitive enough to 
capture the subtler effects of hearing problems and treatments on QoL. The two QoL 
questionnaires that are currently used in patients with a BCHD are the Glasgow Benefit 
Inventory (GBI) and disease-specific Abbreviated Profile of Hearing Aid Benefit (APHAB). 
These lack data related to comfort, ear discharge, pain and hours of use.  
 
How these questions can be addressed  
a) A service evaluation of current UK BCHD practice; development of a national registry of 
BCHDs 
There was consensus among participants that an evaluation of current BCHD practices and 
services delivered nationally (and internationally) would provide important information on 
patient selection and models of service delivery. A qualitative analysis of the factors, 
individual and contextual, that influence decision making and strategies chosen by 
professionals involved in BCHD provision will provide key insight as to why practice may 
vary. This will also inform the development of a prospective (inter)national registry of 
BCHDs, which was considered by participants the best tool for future mapping and 
evaluating outcomes of existing practices. Through the registry, data can be collected on: 
patients (e.g. demographics, otological and audiological history, indications), devices, and 
outcomes (e.g. audiological, comfort, complications, cost, QoL). It was emphasised that 
finding the optimum dataset size would be essential: too large will hamper data completion 
and too small will limit its usefulness. Enabling patients to access and input data into the 
registry would facilitate data collection and shared decision-making. Participants were aware 
  
of existing registries upon which an (inter)national registry could build, such as the Ear 
Foundation Bone Conducting Hearing Implant Registry (The Ear Foundation, 2015) and 
those set up by device companies (AuditBase, 2016). It was also suggested that a future 
registry could be linked to Hospital Episode Statistics (HES) data, for data validation. As 
sources of funding for initial registry development, charities, professional organisations, 
industry and industry were proposed, with research programmes and projects utilising 
registry data and funded by larger grants from major funders (e.g. NIHR, MRC, EU Horizon 
2020) providing resources to sustain the registry. Participants recognised that the 
development of a registry would face challenges, and therefore it would be important to 
engage with all stakeholders including patients from its inception. Piloting a registry in select 
centres providing a valuable learning experience prior to national roll-out was considered 
important. Participants felt that randomised controlled trials comparing BCHD approaches 
and devices may currently not be the most cost-effective method to answer fundamental 
questions in BCHDs; rather conducting future trials within a national registry would provide 
value.  
 
b) Qualitative research to understand patient information and support needs; development of 
patient decision support tools  
Participants felt that an initial step could involve a systematic review with a qualitative meta-
synthesis looking at the existing research around patient information needs on BCHDs pre 
and post implantation, and identifying gaps in knowledge. It was reported that some 
qualitative research is ongoing to identify patient information and decision needs on BCHDs, 
such as that being carried out by the Ear Foundation (The Ear Foundation, 2016). This and 
further qualitative work, focused on specific questions raised from the meta-synthesis, could 
inform the development of patient decision aids for BCHDs. These should follow 
  
international Patient Decision Aids Standards (Elwyn et al., 2006) with involvement of 
patients and clinicians and should be tested in practice. To map patient needs and preferences 
for post-implant support, and develop and test support models it was felt that a collaborative 
approach with patients was important.  
 
c) Development of core outcome sets (COSs) for BCHDs  
A solution to the lack of consistency in outcome measurement in patients with BCHDs would 
be standardisation through the development of ‘core outcome sets’ (COSs) for BCHD, a 
minimum set of outcomes agreed by patients, carers and professionals that should be 
measured and reported in all clinical research. COSs could be embedded within a national 
registry of BCHDs facilitating research including trials within the registry. Participants raised 
that research has already been initiated around COS in this area (Tysome et al., 2015), and in 
the first instance a careful literature review would be necessary. The development of COSs 
for BCHDs would require a structured process involving various stakeholders to define 
‘what’ should be measured and ‘how’ and ‘when’ - that is the appropriate methods and 
timing to quantify these outcomes. It was also emphasised that the COSs and corresponding 
instruments should be validated across different BCHD patient groups and receive patient 
input during development. Proposed UK initiatives providing guidance in this process were 
the University of Oxford Innovation Clinical Outcomes Assessments (Oxford University 
Innovation, 2016) and COMET (COMET Initiative, 2016).  
 
Discussion and conclusion 
This workshop represents a unique approach, building upon the 2015 UK Research Agenda 
for ENT, Hearing and Balance care, bringing together BCHD stakeholders and patients to 
refine UK-specific research priorities in BCHD research. Importantly, this inclusive approach 
  
will promote stakeholder engagement, buy-in, and (inter)national collaboration, producing 
BCHD research that can have an impact on patient care and (inter)national policy.  
This approach can be used to refine research priorities in other areas of ENT, Hearing and 
Balance research. 
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